← Leaderboards
Jiayuh Lin
University Of Michigan At Ann Arbor
$5,012,132
Attributed
$5,871,835
Total exposure
9
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $884.3K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,871,835 · 8
VA$0 · 1
By mechanism
R01$2,694,513 · 2
P01$1,613,229 · 1
R21$1,411,453 · 4
R03$152,640 · 1
I01$0 · 1
Top collaborators
- Chenglong Li6 shared
Most similar at University Of Michigan At Ann Arbor
Same institution · by research overlap
- Peter K Henke$8,173,091
- David Alan Fox$8,525,791
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorPathway InteractionsTumor GrowthCell SurvivalSignal TransductionApoptosisMouse ModelIn Vivo ModelMalignant NeoplasmsPhosphorylationPrimary NeoplasmInhibitor/AntagonistStat3 ProteinClinical TrialsCell ProliferationBiological AvailabilityAngiogenesisSmall MoleculeMolecularOralIn VivoNeoplastic CellIn VitroCells
Grant awards (29)
Dual inhibition of PARP and STAT3 as a novel therapeutic approach for triple-negative breast cancer$181,180
R21 · FY2025 · CA · contact PI
Dual inhibition of PARP and STAT3 as a novel therapeutic approach for triple-negative breast cancer$230,361
R21 · FY2024 · CA · contact PI
Co-Targeting IL-6 and CDK4/6 Pathways as a Novel Approach of Preventive Therapy for Triple-Negative Breast Cancer$0
I01 · FY2024 · VA · contact PI
Co-Targeting IL-6 and CDK4/6 Pathways as a Novel Approach of Preventive Therapy for Triple-Negative Breast Cancer$0
I01 · FY2023 · VA · contact PI
Co-Targeting IL-6 and CDK4/6 Pathways as a Novel Approach of Preventive Therapy for Triple-Negative Breast Cancer$0
I01 · FY2022 · VA · contact PI
A novel STAT3-selective inhibitor for medulloblastoma therapy$335,740
R01 · FY2020 · NS · contact PI
A novel STAT3-selective inhibitor for medulloblastoma therapy$339,473
R01 · FY2019 · NS · contact PI
A novel STAT3-selective inhibitor for medulloblastoma therapy$339,684
R01 · FY2017 · NS · contact PI
THE ROLE OF STAT3 SIGNALING IN CHILDHOOD SARCOMAS$335,087
P01 · FY2017 · CA · contact PI
A novel STAT3-selective inhibitor for medulloblastoma therapy$353,525
R01 · FY2016 · NS · contact PI
THE ROLE OF STAT3 SIGNALING IN CHILDHOOD SARCOMAS$332,396
P01 · FY2016 · CA · contact PI
Repositioning Bazedoxifene as a novel IL-6/GP130 inhibitor for sarcoma therapy$156,785
R21 · FY2016 · CA · contact PI
Repositioning Bazedoxifene as a novel IL-6/GP130 inhibitor for sarcoma therapy$41,613
R21 · FY2016 · CA · contact PI
A novel STAT3-selective inhibitor for medulloblastoma therapy$340,635
R01 · FY2015 · NS · contact PI
THE ROLE OF STAT3 SIGNALING IN CHILDHOOD SARCOMAS$320,415
P01 · FY2015 · CA · contact PI
Repositioning Bazedoxifene as a novel IL-6/GP130 inhibitor for sarcoma therapy$175,974
R21 · FY2015 · CA · contact PI
THE ROLE OF STAT3 SIGNALING IN CHILDHOOD SARCOMAS$308,048
P01 · FY2014 · CA · contact PI
THE ROLE OF STAT3 SIGNALING IN CHILDHOOD SARCOMAS$317,283
P01 · FY2013 · CA · contact PI
Target Stat3 in pancreatic cancer using novel small molecule inhibitors$161,040
R21 · FY2010 · CA · contact PI
A new curcumin analogue with potent suppressive activity in pancreatic cancer$76,320
R03 · FY2010 · CA · contact PI
Target Stat3 in pancreatic cancer using novel small molecule inhibitors$202,835
R21 · FY2009 · CA · contact PI
A new curcumin analogue with potent suppressive activity in pancreatic cancer$76,320
R03 · FY2009 · CA · contact PI
Regulation of Stat3 by p53 in cancer Cells$231,087
R01 · FY2005 · CA
Evaluation of a novel AKT inhibitor in ovarian cancer$127,800
R21 · FY2005 · CA
Regulation of Stat3 by p53 in cancer Cells$242,725
R01 · FY2004 · CA
Evaluation of a novel AKT inhibitor in ovarian cancer$133,865
R21 · FY2004 · CA
Regulation of Stat3 by p53 in cancer Cells$11,638
R01 · FY2004 · CA
Regulation of Stat3 by p53 in cancer Cells$254,363
R01 · FY2003 · CA
Regulation of Stat3 by p53 in cancer Cells$245,643
R01 · FY2002 · CA